Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Evaluation of Cognitive Education Activities in Breast Cancer Patients Receiving Chemotherapy

29 april 2026 bijgewerkt door: Gizem Erdoğan, Saglik Bilimleri Universitesi

Evaluation of Cognitive Education Activities Provided to Breast Cancer Patients Receiving Chemotherapy

Breast cancer is one of the most common cancer types worldwide and accounts for approximately 31% of all cancers in women. The global incidence of breast cancer is increasing, making it a significant public health problem. Advances in breast cancer management, including surgery, chemotherapy, radiotherapy, and hormone therapy, have contributed to reduced mortality rates. However, despite these positive developments, chemotherapy-related cognitive impairment, commonly referred to as "chemobrain," may occur.

Chemotherapy-induced cognitive impairment may manifest as deficits in memory, learning, attention, motor functions, executive functions, visual-spatial abilities, and information processing speed. These impairments negatively affect patients' quality of life and daily functioning.

In this study, cognitive education activities were designed and implemented to address these impairments. These activities aimed to support attention, memory, and executive functions and to minimize cognitive deficits. The purpose of this study was to examine the effects of cognitive activities applied to breast cancer patients receiving chemotherapy on cognitive functions, depression levels, and odor recognition abilities.

The study sought to answer the following research questions:

  1. What is the effect of cognitive education activities on odor recognition ability in breast cancer patients receiving chemotherapy?
  2. What is the effect of cognitive education activities on cognitive functions in breast cancer patients receiving chemotherapy?
  3. What is the effect of cognitive education activities on depression levels in these patients?

Studie Overzicht

Gedetailleerde beschrijving

This randomized controlled trial was conducted between March 2025 and February 2026 at the oncology outpatient clinic and chemotherapy unit of Gulhane Training and Research Hospital. The study aimed to evaluate the effects of cognitive education activities on cognitive function, depression levels, and odor recognition ability in breast cancer patients receiving chemotherapy. A total of 120 patients who met the inclusion criteria were enrolled in the study. Eligible participants were between 18 and 65 years of age, literate, diagnosed with breast cancer, had received at least one cycle of chemotherapy, were continuing treatment, and had no diagnosed neurological or cognitive disorder before or during chemotherapy. In addition, participants had a Standardized Mini-Mental Test (SMMT) score of 24 or below. Participants were randomly assigned to intervention (n=60) and control (n=60) groups using a computer-generated randomization method. During the study, 12 participants withdrew for various reasons, and the study was completed with 108 participants (54 in each group). The study was designed as a single-blind, pre-test/post-test randomized controlled trial. The intervention group received structured cognitive education through printed booklets, face-to-face sessions, and weekly telephone counseling. The cognitive activity program was designed to stimulate attention, memory, executive functions, and language skills. Four cognitive activity booklets with progressively increasing difficulty levels were developed. Since chemotherapy sessions were scheduled every three weeks according to the hospital protocol, each booklet was structured to be completed over a three-week period. Face-to-face sessions were conducted every three weeks, resulting in a total of five sessions over a 12-week period. During these sessions, participants completed structured cognitive activities included in the activity booklets, such as sudoku, puzzles, sentence completion, pattern recognition, word derivation, coloring, and reading comprehension exercises, all of which were designed to support cognitive functions. Weekly telephone follow-ups were conducted to enhance adherence to the intervention. To assess olfactory function, odor identification tasks were performed using non-transparent containers. Familiar scents such as lavender, coffee, lemon, orange, onion, rose water, and cinnamon were used. The control group received routine care without any cognitive intervention during the study period. After completion of the study, the control group was also provided with cognitive activity training and the educational materials used in the intervention. Data were collected using a sociodemographic data form, an odor identification test, the Standardized Mini-Mental Test (SMMT), the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) scale (Version 3), and the Beck Depression Inventory (BDI). Measurements were conducted at baseline and at 12 weeks following the initial assessment.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

108

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Etlik
      • Ankara, Etlik, Turkije (Türkiye), 06010
        • Health Sciences University Gulhane Training and Research Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

Participants were eligible if they met all of the following criteria:

  • Aged between 18 and 65 years
  • Literate
  • Diagnosed with breast cancer
  • Had received at least one cycle of chemotherapy and were currently undergoing chemotherapy
  • Had a Standardized Mini-Mental Test (SMMT) score of 24 or below
  • Had no diagnosed cognitive, neurological, or psychiatric disorder prior to chemotherapy

Exclusion Criteria:

Participants were excluded if they met any of the following criteria:

  • Age over 65 years
  • SMMT score above 24
  • Presence of brain metastases
  • Presence of neurological or medical conditions affecting cognitive function
  • Diagnosed psychiatric disorder
  • Current use of central nervous system depressants, stimulants, or psychiatric medications
  • History of alcohol or substance abuse

Withdrawal Criteria:

Participants were withdrawn from the study if any of the following occurred:

  • Discontinuation of chemotherapy treatment
  • Inability to attend follow-up visits regularly
  • Failure to complete the cognitive activity booklet tasks
  • Loss of contact or inability to reach the participant
  • Voluntary withdrawal from the study
  • Death during the study period

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Geen tussenkomst: Control Group (Routine Care)
Participants in the control group received routine chemotherapy follow-up and standard care without any additional cognitive intervention during the study period.
Experimenteel: Intervention Group (Cognitive Education)
Participants in the intervention group received structured cognitive function training activities in addition to routine care. The intervention was delivered using printed activity booklets designed to support cognitive function.
Participants received structured cognitive training through printed activity booklets designed to support attention, memory, executive functions, and language skills. The booklets included activities such as puzzles, word derivation, sentence completion, pattern recognition, coloring, reading comprehension, and sudoku. Four booklets with progressively increasing difficulty levels were provided over a 12-week period. Each booklet was designed to be completed over three weeks. The intervention was supported by face-to-face sessions and weekly telephone follow-ups to enhance adherence.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Cognitive Function (Standardized Mini-Mental Test)
Tijdsspanne: From baseline to the end of the 12-week intervention period
Cognitive function was assessed using the Standardized Mini-Mental State Examination (SMMSE/SMMT). The scale evaluates global cognitive status across domains including orientation, registration, attention and calculation, recall, and language. Scores range from 0 to 30, where 30 represents maximum cognitive function and scores below 24 may indicate cognitive impairment. Higher scores indicate better cognitive performance.
From baseline to the end of the 12-week intervention period

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Subjective Cognitive Function (Functional Assessment of Cancer Therapy - Cognitive Function)
Tijdsspanne: From baseline to the end of the 12-week intervention period
Subjective cognitive function was assessed using the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3. This self-report scale consists of 37 items categorised into four subscales: Perceived Cognitive Impairment, Comments from Others, Perceived Cognitive Abilities, and Impact of Cognitive Impairment on Quality of Life. Each item is rated on a 5-point Likert scale (0=Not at all to 4=Very much), with higher total scores indicating better perceived cognitive health and fewer cognitive complaints.
From baseline to the end of the 12-week intervention period
Change in Depression Level (Beck Depression Inventory)
Tijdsspanne: From baseline to the end of the 12-week intervention period
Depression levels were assessed using the Beck Depression Inventory (BDI), a 21-item self-report scale evaluating the severity of depressive symptoms. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms.
From baseline to the end of the 12-week intervention period
Odor Recognition Ability
Tijdsspanne: From baseline to the end of the 12-week intervention period
Odor recognition ability was assessed using a structured odor identification test consisting of 8 common odors presented in opaque (non-transparent) containers. Participants were asked to smell each container and indicate whether they could correctly recognize the odor. The assessment was based on whether each odor was correctly identified or not, rather than a numerical scoring system. The odors included familiar scents such as coffee, lavender, lemon, orange, onion, rose water, cinnamon, and mint.
From baseline to the end of the 12-week intervention period

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Gizem Erdoğan, Hemşire, Health Sciences University Gulhane Training and Research Hospital
  • Studie directeur: Betülay Kılıç, Doçent Doktor, Health Sciences University Gülhane Faculty of Nursing

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

3 maart 2025

Primaire voltooiing (Werkelijk)

24 februari 2026

Studie voltooiing (Werkelijk)

2 maart 2026

Studieregistratiedata

Eerst ingediend

9 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

29 april 2026

Eerst geplaatst (Werkelijk)

6 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

29 april 2026

Laatst geverifieerd

1 april 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data will not be shared publicly. The data were collected as part of a single-center randomized controlled trial conducted for academic thesis purposes and will not be made available for external use.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren